Equities Analysts Offer Predictions for XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Leerink Partnrs reduced their FY2026 EPS estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($3.54) per share for the year, down from their prior estimate of ($3.40). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

XENE has been the subject of a number of other research reports. Wedbush dropped their target price on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright initiated coverage on Xenon Pharmaceuticals in a research note on Tuesday, October 1st. They set a “buy” rating and a $53.00 price objective on the stock. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $57.45.

Xenon Pharmaceuticals Price Performance

XENE opened at $43.31 on Friday. The business has a fifty day simple moving average of $39.90 and a 200 day simple moving average of $40.16. Xenon Pharmaceuticals has a 1 year low of $27.99 and a 1 year high of $50.99. The company has a market capitalization of $3.27 billion, a PE ratio of -15.98 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.05). During the same period in the prior year, the company posted ($0.72) earnings per share.

Institutional Trading of Xenon Pharmaceuticals

Several large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in Xenon Pharmaceuticals by 0.9% in the first quarter. California State Teachers Retirement System now owns 56,477 shares of the biopharmaceutical company’s stock valued at $2,431,000 after buying an additional 490 shares in the last quarter. ProShare Advisors LLC increased its holdings in Xenon Pharmaceuticals by 12.0% in the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 565 shares in the last quarter. Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares during the last quarter. Arizona State Retirement System raised its position in Xenon Pharmaceuticals by 4.0% in the second quarter. Arizona State Retirement System now owns 17,949 shares of the biopharmaceutical company’s stock valued at $700,000 after purchasing an additional 688 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Xenon Pharmaceuticals by 1.6% during the second quarter. Envestnet Asset Management Inc. now owns 48,946 shares of the biopharmaceutical company’s stock valued at $1,908,000 after purchasing an additional 769 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.